Hormone receptor‐positive and HER2‐negative breast cancers constitute 60%–70% of breast cancer cases [1] and show the highest dependence on the cyclin D‐CDK4/6 signalling pathway among breast cancer subtypes. Here, ERBB2 is linked to breast carcinoma.